Analysts See $-0.67 EPS for Millendo Therapeutics, Inc. (MLND)

Analysts expect Millendo Therapeutics, Inc. (NASDAQ:MLND) to report $-0.67 EPS on May, 9.They anticipate $2.18 EPS change or 76.49 % from last quarter’s $-2.85 EPS. The stock increased 0.12% or $0.02 during the last trading session, reaching $16.32. About 10,808 shares traded. Millendo Therapeutics, Inc. (NASDAQ:MLND) has declined 10.05% since May 8, 2018 and is downtrending. It has underperformed by 14.42% the S&P500.

Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company has market cap of $218.00 million. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. It currently has negative earnings.

More notable recent Millendo Therapeutics, Inc. (NASDAQ:MLND) news were published by: which released: “Provident Financial (PFS) is a Top Dividend Stock Right Now: Should You Buy? – Yahoo Finance” on March 13, 2019, also with their article: “The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings – Yahoo Finance” published on March 05, 2019, published: “Mitcham Industries Reports Fiscal 2019 First Quarter Results – PR Newswire” on June 06, 2018. More interesting news about Millendo Therapeutics, Inc. (NASDAQ:MLND) were released by: and their article: “Apr 04, 2019 – Tibra Equities Europe Ltd Buys Union Pacific Corp, Walmart Inc, SPDR Select Sector Fund – Consumer Staples, Sells SPDR S&P Oil & Gas Explor & Product, Oracle Corp, Apple Inc –” published on April 04, 2019 as well as‘s news article titled: “Mitcham Industries Announces Revolutionary New Patent-Pending Technology That Could Redefine Ocean Imaging – PRNewswire” with publication date: April 08, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.